Literature DB >> 14667197

Multiparametric analysis of immature cell populations in umbilical cord blood and bone marrow.

Colin P McGuckin1, Daniel Pearce, Nicolas Forraz, Jennifer A Tooze, Suzanne M Watt, Ruth Pettengell.   

Abstract

Adult stem cells are finding increased therapeutic potential not least in tissue regeneration protocols. The cell sources being proposed for such protocols include embryonic, umbilical cord blood (CB) and adult bone marrow (BM). Although embryonic sources are controversial, CB and marrow are available immediately. The appropriate cells of use in these sources are considered to be extremely rare and a characterisation of the starting cell source is important for the development of adult stem cell protocols and ex vivo expansion. Umbilical CB and BM mononuclear cells were labelled for the antigens CD34, CD133, CD117, CD164, Thy-1 or CD38, and additional intracellular CD34 antigen. Three dimensional flow-cytometric analyses were carried out together with dual laser confocal microscope analysis for antigen profile expression. Variable levels of immaturity were detected on CB and BM populations using internal and external CD34 antigen. For CB and BM cells, internal CD34 (intCD34+) could be detected on co-expressing CD133+ cells before expression of external CD34 antigen (extCD34+). CD38 co-expression analysis also showed that a small but distinct group of cells expressing low CD38 and no external CD34 antigen could be detected. Additional phenotyping of these cells using CD117, Thy-1, CD164 and CD133 demonstrated variable primitive status detectable within the external CD34- population. Newly harvested primary CB and BM populations were shown to contain not only cellular populations of known standard sequential maturity but also populations of more extreme rarity. The presence of cells which lacked extracellular CD34 antigen, in both CB and BM, but which possessed CD133, has important implications for purification of human stem cells in clinical applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667197     DOI: 10.1034/j.1600-0609.2003.00153.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  15 in total

1.  Production of stem cells with embryonic characteristics from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz; M-O Baradez; S Navran; J Zhao; R Urban; R Tilton; L Denner
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

Review 2.  Potential for access to embryonic-like cells from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 3.  Promising new sources for pluripotent stem cells.

Authors:  Christian Leeb; Marcin Jurga; Colin McGuckin; Richard Moriggl; Lukas Kenner
Journal:  Stem Cell Rev Rep       Date:  2010-03       Impact factor: 5.739

Review 4.  The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.

Authors:  N Forraz; C P McGuckin
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

5.  Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product.

Authors:  L Bai; L Peters; W Xia; G Best; K Wong; C Ward; M Greenwood
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

Review 6.  The benefits and risks of stem cell technology.

Authors:  A Leventhal; G Chen; A Negro; M Boehm
Journal:  Oral Dis       Date:  2011-11-18       Impact factor: 3.511

7.  Thrombopoietin, flt3-ligand and c-kit-ligand modulate HOX gene expression in expanding cord blood CD133 cells.

Authors:  C P McGuckin; N Forraz; R Pettengell; A Thompson
Journal:  Cell Prolif       Date:  2004-08       Impact factor: 6.831

8.  Human umbilical cord blood cells alter blood and spleen cell populations after stroke.

Authors:  J E Golden; M Shahaduzzaman; A Wabnitz; S Green; T A Womble; P R Sanberg; K R Pennypacker; A E Willing
Journal:  Transl Stroke Res       Date:  2012-09-04       Impact factor: 6.829

9.  Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin.

Authors:  L Denner; Y Bodenburg; J G Zhao; M Howe; J Cappo; R G Tilton; J A Copland; N Forraz; C McGuckin; R Urban
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

10.  A Novel High-Throughput Screening Platform Reveals an Optimized Cytokine Formulation for Human Hematopoietic Progenitor Cell Expansion.

Authors:  Marina Tarunina; Diana Hernandez; Barbara Kronsteiner-Dobramysl; Philip Pratt; Thomas Watson; Peng Hua; Francesca Gullo; Mark van der Garde; Youyi Zhang; Lilian Hook; Yen Choo; Suzanne M Watt
Journal:  Stem Cells Dev       Date:  2016-09-30       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.